Exploratory analysis of serum CA-125 response to surgery and the risk of relapse in patients with FIGO stage IIIC ovarian cancer

Gynecologic Oncology

Volumn 115, Issue 2, 2009, Pages 209-214

  Zivanovic, Oliver ^a   Sima, Camelia S ^a   Iasonos, Alexia ^a   Bell McGuinn, Katherine M ^a   Sabbatini, Paul J ^a   Leitao, Mario M ^a   Levine, Douglas A ^a   Gardner, Ginger J ^a   Barakat, Richard R ^a   Chi, Dennis S ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Advanced epithelial ovarian cancer; CA 125; Ovarian cancer; Perioperative serum CA 125 changes; Surgery

Indexed keywords

ANTINEOPLASTIC AGENT; ANTINEOPLASTIC METAL COMPLEX; CA 125 ANTIGEN; TAXANE DERIVATIVE;

ADULT; AGED; ARTICLE; BLOOD SAMPLING; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER RELAPSE; CANCER STAGING; CYTOREDUCTIVE SURGERY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; OVARY CARCINOMA; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN BLOOD LEVEL;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CA-125 ANTIGEN; COMBINED MODALITY THERAPY; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; MIDDLE AGED; NEOPLASM STAGING; ORGANOPLATINUM COMPOUNDS; OVARIAN NEOPLASMS; PROPORTIONAL HAZARDS MODELS; RECURRENCE;

EID: 70349756686     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2009.06.038     Document Type: Article

References (27)

1. Jemal A., Siegel R., Ward E., Hao Y., Xu J., Murray T., et al. Cancer statistics, 2008. CA Cancer J. Clin. 58 (2008) 71-96
2. Bast Jr. R.C., Feeney M., Lazarus H., Nadler L.M., Colvin R.B., and Knapp R.C. Reactivity of a monoclonal antibody with human ovarian carcinoma. J. Clin. Invest. 68 (1981) 1331-1337
3. Bast Jr. R.C., Klug T.L., St John E., Jenison E., Niloff J.M., Lazarus H., et al. A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer. N. Engl. J. Med. 309 (1983) 883-887
4. Rustin G.J., Nelstrop A.E., McClean P., Brady M.F., McGuire W.P., Hoskins W.J., et al. Defining response of ovarian carcinoma to initial chemotherapy according to serum CA 125. J. Clin. Oncol. 14 (1996) 1545-1551
5. Rustin G.J., Quinn M., Thigpen T., du Bois A., Pujade-Lauraine E., Jakobsen A., et al. Re: new guidelines to evaluate the response to treatment in solid tumors (ovarian cancer). J. Natl. Cancer Inst. 96 (2004) 487-488
6. van der Burg M.E., Lammes F.B., van Putten W.L., and Stoter G. Ovarian cancer: the prognostic value of the serum half-life of CA125 during induction chemotherapy. Gynecol. Oncol. 30 (1988) 307-312
7. Gadducci A., Zola P., Landoni F., Maggino T., Sartori E., Bergamino T., et al. Serum half-life of CA 125 during early chemotherapy as an independent prognostic variable for patients with advanced epithelial ovarian cancer: results of a multicentric Italian study. Gynecol. Oncol. 58 (1995) 42-47
8. Riedinger J.M., Wafflart J., Ricolleau G., Eche N., Larbre H., Basuyau J.P., et al. CA 125 half-life and CA 125 nadir during induction chemotherapy are independent predictors of epithelial ovarian cancer outcome: results of a French multicentric study. Ann. Oncol. 17 (2006) 1234-1238
9. Crawford S.M., and Peace J. Does the nadir CA125 concentration predict a long-term outcome after chemotherapy for carcinoma of the ovary?. Ann. Oncol. 16 (2005) 47-50
10. Markman M., Federico M., Liu P.Y., Hannigan E., and Alberts D. Significance of early changes in the serum CA-125 antigen level on overall survival in advanced ovarian cancer. Gynecol. Oncol. 103 (2006) 195-198
11. Juretzka M.M., Barakat R.R., Chi D.S., Iasonos A., Dupont J., Abu-Rustum N.R., et al. CA125 level as a predictor of progression-free survival and overall survival in ovarian cancer patients with surgically defined disease status prior to the initiation of intraperitoneal consolidation therapy. Gynecol. Oncol. 104 (2007) 176-180
12. Markman M., Liu P.Y., Rothenberg M.L., Monk B.J., Brady M., and Alberts D.S. Pretreatment CA-125 and risk of relapse in advanced ovarian cancer. J. Clin. Oncol. 24 (2006) 1454-1458
13. Zorn K.K., Tian C., McGuire W.P., Hoskins W.J., Markman M., Muggia F.M., et al. The prognostic value of pretreatment CA 125 in patients with advanced ovarian carcinoma: a Gynecologic Oncology Group study. Cancer 115 (2009) 1028-1035
14. Sevelda P., Rosen A., Barrada M., Gober S., Vavra N., and Salzer H. Does follow-up of false-negative CA-125 serum values in tumor after-care of ovarian cancer make sense?. Gynakol. Rundsch. 30 Suppl 1 (1990) 210-211
15. Yedema C.A., Kenemans P., Thomas C.M., Massuger L.F., Wobbes T., Verstraeten R., et al. CA 125 serum levels in the early post-operative period do not reflect tumour reduction obtained by cytoreductive surgery. Eur J Cancer 29A (1993) 966-971
16. Gadducci A., Landoni F., Maggino T., Sartori E., Zola P., and Fanucchi A. The relationship between postoperative decline of serum CA 125 levels and size of residual disease after initial surgery in patients with advanced ovarian cancer: a CTF study. Gynecol. Oncol. 63 (1996) 234-237
17. Vergote I., Rustin G.J., Eisenhauer E.A., Kristensen G.B., Pujade-Lauraine E., Parmar M.K., et al. Re: new guidelines to evaluate the response to treatment in solid tumors [ovarian cancer]. Gynecologic Cancer Intergroup. J. Natl. Cancer Inst. 92 (2000) 1534-1535
18. Rustin G.J., Nelstrop A.E., Tuxen M.K., and Lambert H.E. Defining progression of ovarian carcinoma during follow-up according to CA 125: a North Thames Ovary Group Study. Ann. Oncol. 7 (1996) 361-364
19. Rustin G.J., Marples M., Nelstrop A.E., Mahmoudi M., and Meyer T. Use of CA-125 to define progression of ovarian cancer in patients with persistently elevated levels. J. Clin. Oncol. 19 (2001) 4054-4057
20. Lee E., Wei L., and Amato D. Cox-type regression analysis for large numbers of small groups of correlated failure time observations. In: Klein J.P., and Goel P.K. (Eds). Survival analysis: state of the art (1992), Kluwer Academic Publishers, Dordrecht 237-247
21. Winter 3rd W.E., Maxwell G.L., Tian C., Carlson J.W., Ozols R.F., Rose P.G., et al. Prognostic factors for stage III epithelial ovarian cancer: a Gynecologic Oncology Group Study. J. Clin. Oncol. 25 (2007) 3621-3627
22. Armstrong D.K., Bundy B., Wenzel L., Huang H.Q., Baergen R., Lele S., et al. Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N. Engl. J. Med. 354 (2006) 34-43
23. Zhang L., Conejo-Garcia J.R., Katsaros D., Gimotty P.A., Massobrio M., Regnani G., et al. Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N. Engl. J. Med. 348 (2003) 203-213
24. Cass I., Baldwin R.L., Varkey T., Moslehi R., Narod S.A., and Karlan B.Y. Improved survival in women with BRCA-associated ovarian carcinoma. Cancer 97 (2003) 2187-2195
25. Rubin S.C., Benjamin I., Behbakht K., Takahashi H., Morgan M.A., LiVolsi V.A., et al. Clinical and pathological features of ovarian cancer in women with germ-line mutations of BRCA1. N. Engl. J. Med. 335 (1996) 1413-1416
26. Boyd J., Sonoda Y., Federici M.G., Bogomolniy F., Rhei E., Maresco D.L., et al. Clinicopathologic features of BRCA-linked and sporadic ovarian cancer. JAMA 283 (2000) 2260-2265
27. Levanon K., Crum C., and Drapkin R. New insights into the pathogenesis of serous ovarian cancer and its clinical impact. J. Clin. Oncol. 26 (2008) 5284-5293